APP and Alzheimer disease: [11C]UCB-J and [18F]SynVesT-1 have been used to study synaptic loss in two AD mouse models, ArcSwe and APP/PS1 (Sadasivam et al., 2021; Xiong et al., 2021), as well as to evaluate the potential effect of treating AD pathology with a Fyn kinase inhibitor, saracatinib (Toyonaga et al., 2019).